Hansoh Pharmaceutical Group Company Limited announce that "Ibrexafungerp Tablets" has been granted a clinical trial approval issued by the National Medical Products Administration of the People's Republic of China. The Group will conduct phase 3 clinical trial for vulvovaginal candidiasis in China. As disclosed in the announcement of the Company dated February 17, 2021, Hansoh Healthtech Company Limited and Jiangsu Hansoh Pharmaceutical Group Co. Ltd., both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China . As at the date of this announcement, the Product has been approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis, being the first new antifungal class in over 20 years, as well as the first and only non-azole treatment for vaginal yeast infections.